Castleman Disease: Retrospective Single-Center Study of Therapeutic Results in 10 Patients
Authors:
P. Szturz 1; Z. Adam 1; Z. Řehák 2; R. Koukalová 2; A. Šprláková-Puková 3; J. Michalka 1; L. Šmardová 1; P. Volfová 1; M. Lengerová 1; J. Mayer 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení nukleární medicíny, PET centrum Masarykova onkologického ústavu v Brně
2; Radiologická klinika LF MU a FN Brno
3
Published in:
Klin Onkol 2013; 26(2): 124-134
Category:
Original Articles
Overview
Background:
Castleman disease is a non-clonal lymphoproliferative disorder with 2 clinical (unicentric, multicentric) and 4 histomorphological (hyaline vascular, plasma cell, mixed, plasmablastic) forms which combine creating a pleomorphic picture of this rare entity. In our work, the largest documented cohort in the Czech Republic was analyzed focusing on diagnostics and particularly on therapy.
Patients and Methods:
The retrospective study (1998–2013) included 10 patients, 6 males, 4 females. Patients with unicentric form (3) underwent surgical sanation. Patients with multicentric form (7) were followed-up only (2) or extirpation of the largest mass was carried out (1) or a systemic therapy was administered (4) which comprised the following regimens: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), CTD/CAD/CVD (cyclophosphamide, thalidomide/adriamycin/bortezomib, dexamethasone), further including monotherapies with tocilizumab, thalidomide and lenalidomide and in one case (associated POEMS syndrome, i.e. polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) autologous stem cell transplantation after melphalan conditioning was performed. During treatment response monitoring, all patients underwent PET/CT examination (fluorodeoxyglucose positron emission tomography/computed tomography).
Results:
The remission rate was 50% (3 unicentric forms with remission lasting 51, 8 and 9 months, resp.; 2 multicentric forms with remission lasting 3 months during thalidomide therapy and 12 months after lenalidomide therapy), stable disease was observed in 40% of cases (multicentric forms, 2 without any treatment followed-up for 171 and 24 months, resp.; 1 after systemic therapy followed-up for 23 months; 1 after two extirpations with stable lymphadenopathy for 15 years, where the first operation was 27 years ago). In one patient (10%), the associated POEMS syndrome progressed rapidly with fatal consequences (4 months follow-up).
Conclusion:
Unlike unicentric forms completely curable by excision, multicentric forms are often treatment-refractory. Concerning high cost-effectiveness, good tolerability and documented efficacy also in rituximab-resistant cases, we prefer immunomodulatory drugs (particularly thalidomide) for managing multicentric Castleman disease in our center.
Key words:
Castleman disease – monoclonal antibody – rituximab – tocilizumab – thalidomide – lenalidomide – positron emission tomography – computed tomography
Sources
1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 1954; 251(10): 396–400.
2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9(4): 822–830.
3. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16(4): 236–246.
4. Dispenzieri A. Castleman disease. In: Ansell SM (ed.). Rare Hematological Malignancies. Boston MA: Springer Science + Business Medie, LLC 2008: 293–330.
5. Bonekamp D, Horton KM, Hruban RH et al. Castleman disease: the great mimic. Radiographics 2011; 31(6): 1793–1807.
6. Ye B, Gao SG, Li W et al. A retrospective study of unicentric and multicentric Castleman‘s disease: a report of 52 patients. Med Oncol 2010; 27(4): 1171–1178.
7. Moore DF, Preti A, Tran SM. Prognostic implications following an indeterminate diagnostic work-up of lymphoma. Blood 1996; 88 (Suppl 1): 229a.
8. Mehra M, Cossrow N, Stellhorn RA et al. Use of a Claims Database to Characterize and Estimate the Incidence of Castleman’s Disease (abstract 4253). Available from: https://ash.confex.com/ash/2012/webprogram/Paper51578.html.
9. Yabuhara A, Yanagisawa M, Murata T et al. Giant lymph node hyperplasia (Castleman‘s disease) with spontaneous production of high levels of B-cell differentiation factor activity. Cancer 1989; 63(2): 260–265.
10. Dossier A, Meignin V, Fieschi C et al. Human Herpesvirus 8-Related Castleman Disease in the Absence of HIV Infection. Clin Infect Dis 2013; 56(6): 833–842.
11. Szturz P, Moulis M, Adam Z et al. Castlemanova choroba. Klin Onkol 2011; 24(6): 424–434.
12. Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87(8): 804–814.
13. Szturz P, Adam Z, Moulis M et al. Naše zkušenosti s léčbou multicentrické plazmocelulární Castlemanovy choroby s projevy vaskulitidy: popis případu a přehled literatury. Vnitr Lek 2012; 58(9): 679–690.
14. Chronowski GM, Ha CS, Wilder RB et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92(3): 670–676.
15. Estephan FF, Elghetany MT, Berry M et al. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman‘s disease. Cancer Invest 2005; 23(2): 191.
16. Bandera B, Ainsworth C, Shikle J et al. Treatment of unicentric Castleman disease with neoadjuvant rituximab. Chest 2010; 138(5): 1239–1241.
17. Lachmann HJ, Gilbertson JA, Gillmore JD et al. Unicentric Castleman‘s disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002; 95(4): 211–218.
18. Herrada J, Cabanillas F, Rice L et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128(8): 657–662.
19. Shin DY, Jeon YK, Hong YS et al. Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 2011; 52(8): 1517–1522.
20. Marti S, Pahissa A, Guardia J et al. Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapy. Cancer 1983; 51(5): 808–810.
21. Sethi T, Joshi K, Sharma SC et al. Radiation therapy in the management of giant lymph node hyperplasia. Br J Radiol 1990; 63(752): 648–650.
22. Frizzera G, Peterson BA, Bayrd ED et al. A systemic lymphoproliferative disorder with morphologic features of Castleman‘s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3(9): 1202–1216.
23. Bowne WB, Lewis JJ, Filippa DA et al. The management of unicentric and multicentric Castleman‘s disease: a report of 16 cases and a review of the literature. Cancer 1999; 85(3): 706–717.
24. Nishimoto N. Clinical studies in patients with Castleman‘s disease, Crohn‘s disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005; 28(3): 221–230.
25. van Rhee F, Fayad L, Voorhees P et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman‘s disease. J Clin Oncol 2010; 28(23): 3701–3708.
26. Ide M, Ogawa E, Kasagi K et al. Successful treatment of multicentric Castleman‘s disease with bilateral orbital tumour using rituximab. Br J Haematol 2003; 121(5): 818–819.
27. Gholam D, Vantelon JM, Al-Jijakli A et al. A case of multicentric Castleman‘s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 2003; 82(12): 766–768.
28. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005; 78(4): 302–305.
29. Bower M, Powles T, Williams S et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147(12): 836–839.
30. Neuville S, Agbalika F, Rabian C et al. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 2005; 79(4): 337–339.
31. Buchler T, Dubash S, Lee V et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman‘s disease with multiorgan failure: report of two cases. AIDS 2008; 22(13): 1685–1687.
32. Fishman SJ, Feins NR, D’Amato RJ et al. Long-term remission of Crohn’s disease treated with thalidomide: a seminal case report. Angiogenesis 1999; 3(3): 201–204.
33. Špička I, Hájek R, Gregora E et al. První zkušenosti s léčbou mnohočetného myelomu v České republice. Klin Onkol 2002; 15 (Suppl): 42–43.
34. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman‘s disease by thalidomide. Am J Hematol 2003; 73(1): 48–53.
35. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006; 81(4): 303–304.
36. Kim SY, Lee SA, Ryoo HM et al. Thalidomide for POEMS syndrome. Ann Hematol 2006; 85(8): 545–546.
37. Wang X, Ye S, Xiong C et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman‘s disease. Jpn J Clin Oncol 2011; 41(10): 1221–1224.
30. Menegato MA, Canelles MF, Tonutti E et al. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman‘s disease. Clin Nephrol 2004; 61(5): 352–356.
39. Miltenyi Z, Toth J, Gonda A et al. Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res 2009; 15(3): 375–381.
40. Zhao X, Shi R, Jin X et al. Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases. J Am Acad Dermatol 2011; 65(2): 430–432.
41. Vallet S, Palumbo A, Raje N et al. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49(7): 1238–1245.
42. Briani C, Manara R, Lessi F et al. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy. Am J Hematol 2012; 87(5): 539–541.
43. Ramasamy K, Gandhi S, Tenant-Flowers M et al. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012; 158(3): 421–423.
44. Stary G, Kohrgruber N, Herneth AM et al. Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. AIDS 2008; 22(10): 1232–1234.
45. Jung CP, Emmerich B, Goebel FD et al. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004; 75(3): 176–177.
46. Weisenburger DD, Nathwani BN, Winberg CD et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985; 16(2): 162–172.
47. Oksenhendler E, Duarte M, Soulier J et al. Multicentric Castleman‘s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10(1): 61–67.
48. Talat N, Schulte KM. Castleman‘s disease: systematic analysis of 416 patients from the literature. Oncologist 2011; 16(9): 1316–1324.
49. Peterson BA, Frizzera G. Multicentric Castleman‘s disease. Semin Oncol 1993; 20(6): 636–647.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2013 Issue 2
Most read in this issue
- Prognostic Factors for Cervical Cancer
- Spontaneous Remission of Acute Myeloid Leukemia – a Single Center Case Reports
- A Case Report: Neutropenia Grade IV and Febrile Neutropenia in a Metastatic Breast Cancer Patient Treated With Palliative Chemotherapy Cyclophosphamide/Myocet
- The Role of Radiotherapy in the Treatment of Malignant Lymphomas – Recommendations of the Czech Lymphoma Study Group